Effects of conventional immunosuppressive treatment on CD244+ (CD28null) and FOXP3+ T cells in the inflamed muscle of patients with polymyositis and dermatomyositis

Arthritis Research and Therapy

Volumn 18, Issue 1, 2016, Pages

  Pandya, Jayesh M ^a   Loell, Ingela ^a   Hossain, Mohammad Shahadat ^a   Zong, Mei ^a   Alexanderson, Helene ^a   Raghavan, Sukanya ^a,b   Lundberg, Ingrid E ^a   Malmström, Vivianne ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UNIVERSITY OF GOTHENBURG   (Sweden)

Author keywords

Glucocorticoids; Inflammation; Myositis; T lymphocyte; Treg cells

Indexed keywords

AZATHIOPRINE; CD244 ANTIGEN; CD3 ANTIGEN; CD69 ANTIGEN; CELL MARKER; CREATINE KINASE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; METHOTREXATE; PREDNISOLONE; TRANSCRIPTION FACTOR FOXP3; UNCLASSIFIED DRUG; CD244 PROTEIN, HUMAN; FORKHEAD TRANSCRIPTION FACTOR; FOXP3 PROTEIN, HUMAN; IMMUNOGLOBULIN RECEPTOR; IMMUNOSUPPRESSIVE AGENT; LEUKOCYTE ANTIGEN; SIGNALING LYMPHOCYTIC ACTIVATION MOLECULE;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DERMATOMYOSITIS; DISABILITY; DISEASE ACTIVITY; FEMALE; FUNCTIONAL ASSESSMENT; FUNCTIONAL INDEX; HEALTH ASSESSMENT QUESTIONNAIRE; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; IN VITRO STUDY; MALE; MANUAL MUSCLE TESTING 8; MUSCLE BIOPSY; MUSCULOSKELETAL DISEASE ASSESSMENT; MYOSITIS INTENTION TO TREAT ACTIVITY INDEX; POLYMYOSITIS; PROGNOSIS; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; IMMUNOHISTOCHEMISTRY; IMMUNOLOGY; IMMUNOPHENOTYPING; MIDDLE AGED; PATHOLOGY; PROSPECTIVE STUDY; SKELETAL MUSCLE; T LYMPHOCYTE SUBPOPULATION; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; DERMATOMYOSITIS; FEMALE; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; POLYMYOSITIS; PROSPECTIVE STUDIES; RECEPTORS, IMMUNOLOGIC; SIGNALING LYMPHOCYTIC ACTIVATION MOLECULE FAMILY; T-LYMPHOCYTE SUBSETS;

EID: 85008625219     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/S13075-016-0974-5     Document Type: Article

References (54)

1. Arahata K, Engel AG. Monoclonal antibody analysis of mononuclear cells in myopathies. I: Quantitation of subsets according to diagnosis and sites of accumulation and demonstration and counts of muscle fibers invaded by T cells. Ann Neurol. 1984;16(2):193-208.
2. Engel AG, Arahata K. Monoclonal antibody analysis of mononuclear cells in myopathies. II: Phenotypes of autoinvasive cells in polymyositis and inclusion body myositis. Ann Neurol. 1984;16(2):209-15.
3. Goebels N, Michaelis D, Engelhardt M, Huber S, Bender A, Pongratz D, et al. Differential expression of perforin in muscle-infiltrating T cells in polymyositis and dermatomyositis. J Clin Invest. 1996;97(12):2905-10.
4. Zong M, Lundberg IE. Pathogenesis, classification and treatment of inflammatory myopathies. Nat Rev Rheumatol. 2011;7(5):297-306.
5. Lundberg IE, Vencovsky J, Alexanderson H. Therapy of myositis: biological and physical. Curr Opin Rheumatol. 2014;26(6):704-11.
6. Bunch TW, Worthington JW, Combs JJ, Ilstrup DM, Engel AG. Azathioprine with prednisone for polymyositis. A controlled, clinical trial. Ann Intern Med. 1980;92(3):365-9.
7. Lundberg I, Kratz AK, Alexanderson H, Patarroyo M. Decreased expression of interleukin-1alpha, interleukin-1beta, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis. Arthritis Rheum. 2000;43(2):336-48.
8. Korotkova M, Helmers SB, Loell I, Alexanderson H, Grundtman C, Dorph C, et al. Effects of immunosuppressive treatment on microsomal prostaglandin E synthase 1 and cyclooxygenases expression in muscle tissue of patients with polymyositis or dermatomyositis. Ann Rheum Dis. 2008;67(11):1596-602.
9. Schirmer M, Vallejo AN, Weyand CM, Goronzy JJ. Resistance to apoptosis and elevated expression of Bcl-2 in clonally expanded CD4 + CD28-T cells from rheumatoid arthritis patients. J Immunol. 1998;161(2):1018-25.
10. Posnett DN, Edinger JW, Manavalan JS, Irwin C, Marodon G. Differentiation of human CD8 T cells: implications for in vivo persistence of CD8+ CD28- cytotoxic effector clones. Int Immunol. 1999;11(2):229-41.
11. Vallejo AN, Schirmer M, Weyand CM, Goronzy JJ. Clonality and longevity of CD4 + CD28null T cells are associated with defects in apoptotic pathways. J Immunol. 2000;165(11):6301-7.
12. Kovalcsik E, Antunes RF, Baruah P, Kaski JC, Dumitriu IE. Proteasomemediated reduction in proapoptotic molecule Bim renders CD4(+)CD28null T cells resistant to apoptosis in acute coronary syndrome. Circulation. 2015;131(8):709-20.
13. Namekawa T, Snyder MR, Yen JH, Goehring BE, Leibson PJ, Weyand CM, et al. Killer cell activating receptors function as costimulatory molecules on CD4 + CD28null T cells clonally expanded in rheumatoid arthritis. J Immunol. 2000;165(2):1138-45.
14. Fasth AE, Cao D, van Vollenhoven R, Trollmo C, Malmstrom V. CD28nullCD4+ T cells-characterization of an effector memory T-cell population in patients with rheumatoid arthritis. Scand J Immunol. 2004;60(1-2):199-208.
15. Fasth AE, Bjorkstrom NK, Anthoni M, Malmberg KJ, Malmstrom V. Activating NK-cell receptors co-stimulate CD4(+)CD28(-) T cells in patients with rheumatoid arthritis. Eur J Immunol. 2010;40(2):378-87.
16. Thome JJ, Yudanin N, Ohmura Y, Kubota M, Grinshpun B, Sathaliyawala T, et al. Spatial map of human T cell compartmentalization and maintenance over decades of life. Cell. 2014;159(4):814-28.
17. Fagnoni FF, Vescovini R, Mazzola M, Bologna G, Nigro E, Lavagetto G, et al. Expansion of cytotoxic CD8+ CD28-T cells in healthy ageing people, including centenarians. Immunology. 1996;88(4):501-7.
18. Martens PB, Goronzy JJ, Schaid D, Weyand CM. Expansion of unusual CD4+ T cells in severe rheumatoid arthritis. Arthritis Rheum. 1997;40(6):1106-14.
19. Markovic-Plese S, Cortese I, Wandinger KP, McFarland HF, Martin R. CD4 + CD28-costimulation-independent T cells in multiple sclerosis. J Clin Invest. 2001;108(8):1185-94.
20. Garcia de Tena J, Manzano L, Leal JC, San Antonio E, Sualdea V, Alvarez-Mon M. Active Crohn's disease patients show a distinctive expansion of circulating memory CD4+CD45RO+CD28null T cells. J Clin Immunol. 2004;24(2):185-96.
21. Thewissen M, Somers V, Venken K, Linsen L, van Paassen P, Geusens P, et al. Analyses of immunosenescent markers in patients with autoimmune disease. Clin Immunol. 2007;123(2):209-18.
22. Liuzzo G, Goronzy JJ, Yang H, Kopecky SL, Holmes DR, Frye RL, et al. Monoclonal T-cell proliferation and plaque instability in acute coronary syndromes. Circulation. 2000;101(25):2883-8.
23. Sakaguchi S, Yamaguchi T, Nomura T, Ono M. Regulatory T cells and immune tolerance. Cell. 2008;133(5):775-87.
24. Sakaguchi S, Miyara M, Costantino CM, Hafler DA. FOXP3+ regulatory T cells in the human immune system. Nat Rev Immunol. 2010;10(7):490-500.
25. Castiglioni A, Corna G, Rigamonti E, Basso V, Vezzoli M, Monno A, et al. FOXP3+ T cells recruited to sites of sterile skeletal muscle injury regulate the fate of satellite cells and guide effective tissue regeneration. PLoS One. 2015;10(6):e0128094.
26. Burzyn D, Kuswanto W, Kolodin D, Shadrach JL, Cerletti M, Jang Y, et al. A special population of regulatory T cells potentiates muscle repair. Cell. 2013;155(6):1282-95.
27. Fasth AE, Dastmalchi M, Rahbar A, Salomonsson S, Pandya JM, Lindroos E, et al. T cell infiltrates in the muscles of patients with dermatomyositis and polymyositis are dominated by CD28null T cells. J Immunol. 2009;183(7):4792-9.
28. Pandya JM, Fasth AE, Zong M, Arnardottir S, Dani L, Lindroos E, et al. Expanded T cell receptor Vbeta-restricted T cells from patients with sporadic inclusion body myositis are proinflammatory and cytotoxic CD28null T cells. Arthritis Rheum. 2010;62(11):3457-66.
29. Waschbisch A, Schwab N, Ruck T, Stenner MP, Wiendl H. FOXP3+ T regulatory cells in idiopathic inflammatory myopathies. J Neuroimmunol. 2010;225(1-2):137-42.
30. ThewissenM, Somers V, Hellings N, Fraussen J, Damoiseaux J, Stinissen P. CD4 + CD28null T cells in autoimmune disease: pathogenic features and decreased susceptibility to immunoregulation. J Immunol. 2007;179(10):6514-23.
31. Bohan A, Peter JB. Polymyositis and dermatomyositis (second of two parts). N Engl J Med. 1975;292(8):403-7.
32. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med. 1975;292(7):344-7.
33. Labirua-Iturburu A, Selva-O'Callaghan A, Vincze M, Danko K, Vencovsky J, Fisher B, et al. Anti-PL-7 (anti-threonyl-tRNA synthetase) antisynthetase syndrome: clinical manifestations in a series of patients from a European multicenter study (EUMYONET) and review of the literature. Medicine. 2012;91(4):206-11.
34. Henriksson KG, Sandstedt P. [Polymyositis]. Scand J Rheumatol Suppl. 1979;30:200-6.
35. Dorph C, Nennesmo I, Lundberg IE. Percutaneous conchotome muscle biopsy. A useful diagnostic and assessment tool. J Rheumatol. 2001;28(7):1591-9.
36. Raghavan S, Cao D, Widhe M, Roth K, Herrath J, Engstrom M, et al. FOXP3 expression in blood, synovial fluid and synovial tissue during inflammatory arthritis and intra-articular corticosteroid treatment. Ann Rheum Dis. 2009;68(12):1908-15.
37. Josefson A, Romanus E, Carlsson J. A Functional Index in myositis. J Rheumatol. 1996;23:1380-4.
38. Hay EM, Bacon PA, Gordon C, Isenberg DA, Maddison P, Snaith ML, et al. The BILAG index: a reliable and valid instrument for measuring clinical disease activity in systemic lupus erythematosus. Q J Med. 1993;86(7):447-58.
39. Rider LG, Koziol D, Giannini EH, Jain MS, Smith MR, Whitney-Mahoney K, et al. Validation of manual muscle testing and a subset of eight muscles for adult and juvenile idiopathic inflammatory myopathies. Arthritis Care Res (Hoboken). 2010;62(4):465-72.
40. Alexanderson H, Lundberg IE, Stenstrom CH. Development of the myositis activities profile-validity and reliability of a self-administered questionnaire to assess activity limitations in patients with polymyositis/dermatomyositis. J Rheumatol. 2002;29(11):2386-92.
41. Munro BH. Statistical methods for health care research. 5th ed. Philadelphia: Lippincott Williams & Wilkins; 2005.
42. Fasth AE, Snir O, Johansson AA, Nordmark B, Rahbar A, Af Klint E, et al. Skewed distribution of proinflammatory CD4+CD28null T cells in rheumatoid arthritis. Arthritis Res Ther. 2007;9(5):R87.
43. Namekawa T, Wagner UG, Goronzy JJ. Functional subsets of CD4 T cells in rheumatoid synovitis. Arthritis Rheum. 1998;41:2108-16.
44. Tidball JG, Villalta SA. Regulatory interactions between muscle and the immune system during muscle regeneration. Am J Physiol Regul Integr Comp Physiol. 2010;298(5):R1173-87.
45. Pandya JM, Venalis P, Al-Khalili L, Hossain MS, Stache V, Lundberg IE, et al. CD4+ and CD8+ CD28null T cells are cytotoxic to autologous muscle cells in polymyositis patients. Arthritis Rheumatol. 2016. doi: 10.1002/art.39650. [Epub ahead of print].
46. Gold R, Buttgereit F, Toyka KV. Mechanism of action of glucocorticosteroid hormones: possible implications for therapy of neuroimmunological disorders. J Neuroimmunol. 2001;117(1-2):1-8.
47. Ashwell JD, Lu FW, Vacchio MS. Glucocorticoids in T cell development and function. Annu Rev Immunol. 2000;18:309-45.
48. Arruda VR, Favaro P, Finn JD. Strategies to modulate immune responses: a new frontier for gene therapy. Mol Ther. 2009;17(9):1492-503.
49. Effros RB. Replicative senescence: impact on T cell immunity in the elderly. Aging. 1998;10(2):152.
50. Sharpless NE, DePinho RA. Telomeres, stem cells, senescence, and cancer. J Clin Invest. 2004;113(2):160-8.
51. Chou JP, Effros RB. T cell replicative senescence in human aging. Curr Pharm Des. 2013;19(9):1680-98.
52. Wust S, van den Brandt J, Tischner D, Kleiman A, Tuckermann JP, Gold R, et al. Peripheral T cells are the therapeutic targets of glucocorticoids in experimental autoimmune encephalomyelitis. J Immunol. 2008;180(12):8434-43.
53. Hodge G, Jersmann H, Tran HB, Holmes M, Reynolds PN, Hodge S. Lymphocyte senescence in COPD is associated with loss of glucocorticoid receptor expression by pro-inflammatory/cytotoxic lymphocytes. Respir Res. 2015;16:2.
54. Weyand CM, Brandes JC, Schmidt D, Fulbright JW, Goronzy JJ. Functional properties of CD4+ CD28-T cells in the aging immune system. Mech Ageing Dev. 1998;102(2-3):131-47.